The hospital is committed to adding to specialised practices in the healthcare space with its pioneering effort to promote oral health awareness and tobacco addiction prevention
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
With this move, government hospitals across India can now access the geko device to prevent life-threatening blood clots, and address complications related to swelling following orthopaedic surgery and the healing of chronic wounds (leg ulcers)
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Subscribe To Our Newsletter & Stay Updated
